AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation
Go back to AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation| AbbVie (NYSE: ABBV) | Delayed: 255.48 -2.67 (1.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $258.15 | 52 Week High | $68.12 | |||
| Open | $258.67 | 52 Week Low | $50.71 | |||
| Day High | $259.00 | P/E | 55.42 | |||
| Day Low | $255.08 | EPS | $4.61 | |||
| Volume | 3,224,810 | |||||
| ENANTA PHARM (NASDAQ: ENTA) | Delayed: 13.60 -0.2 (1.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.80 | 52 Week High | $34.49 | |||
| Open | $13.72 | 52 Week Low | $20.39 | |||
| Day High | $13.91 | P/E | N/A | |||
| Day Low | $13.47 | EPS | $-3.18 | |||
| Volume | 155,916 | |||||
